Shares of French biotech company Innate Pharma SA were on the rise on Thursday in premarket trading. The stock gained 23% after Wall Street learned that the European Medicines Agency had accepted the company’s application for leukemia treatment Lumoxiti. A late-stage clinical trial presented at ASH 2019, revealed that 36% of patients with relapsed or … Continue reading “Innate Pharma Explodes on Leukemia Drug Submission in Europe”
